Samuel Le Sourd

3.2k total citations
42 papers, 634 citations indexed

About

Samuel Le Sourd is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Oncology. According to data from OpenAlex, Samuel Le Sourd has authored 42 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 17 papers in Hepatology and 14 papers in Oncology. Recurrent topics in Samuel Le Sourd's work include Hepatocellular Carcinoma Treatment and Prognosis (17 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers). Samuel Le Sourd is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (17 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers). Samuel Le Sourd collaborates with scholars based in France, United States and Taiwan. Samuel Le Sourd's co-authors include Julien Edeline, Marc Pracht, Yan Rolland, Étienne Garin, Karim Boudjéma, Astrid Lièvre, Éveline Boucher, Luc Beuzit, Sophie Laffont and Yann Touchefeu and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Samuel Le Sourd

38 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Le Sourd France	15	316	300	296	227	109	42	634
Beau Toskich United States	15	384 1.2×	168 0.6×	163 0.6×	112 0.5×	106 1.0×	52	528
Cheng‐Hsiang Lo Taiwan	15	230 0.7×	142 0.5×	173 0.6×	129 0.6×	96 0.9×	40	501
Vlasios S. Sotirchos United States	11	369 1.2×	105 0.3×	122 0.4×	165 0.7×	133 1.2×	44	455
Ting‐Shi Su China	15	361 1.1×	195 0.7×	179 0.6×	130 0.6×	84 0.8×	32	589
Leigh Casadaban United States	15	387 1.2×	303 1.0×	105 0.4×	142 0.6×	81 0.7×	25	664
Elias Hohlastos United States	13	637 2.0×	309 1.0×	214 0.7×	106 0.5×	118 1.1×	23	776
Ali Habib United States	12	611 1.9×	347 1.2×	146 0.5×	99 0.4×	86 0.8×	13	741
Zhi-Ping Yan China	13	399 1.3×	199 0.7×	110 0.4×	92 0.4×	64 0.6×	26	542
Yangkui Gu China	11	169 0.5×	137 0.5×	154 0.5×	130 0.6×	48 0.4×	25	425
Patrick McNeillie United States	6	298 0.9×	136 0.5×	183 0.6×	312 1.4×	169 1.6×	13	680

Countries citing papers authored by Samuel Le Sourd

Since Specialization

Citations

This map shows the geographic impact of Samuel Le Sourd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Le Sourd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Le Sourd more than expected).

Fields of papers citing papers by Samuel Le Sourd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Le Sourd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Le Sourd. The network helps show where Samuel Le Sourd may publish in the future.

Co-authorship network of co-authors of Samuel Le Sourd

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Le Sourd. A scholar is included among the top collaborators of Samuel Le Sourd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Le Sourd. Samuel Le Sourd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adenis, Antoine, Guillaume Piessen, Samuel Le Sourd, et al.. (2023). Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.. Journal of Clinical Oncology. 41(4_suppl). 370–370.

McNamara, Mairéad G., Samuel Le Sourd, Ángela Lamarca, et al.. (2023). Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy. British Journal of Cancer. 129(11). 1766–1772. 3 indexed citations

Garin, Étienne, Xavier Palard, Yan Rolland, et al.. (2023). 188Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study). Cancers. 15(8). 2245–2245. 1 indexed citations

Tron, Camille, F. Lemaı̂tre, Thierry Lecomte, et al.. (2022). 449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study. Annals of Oncology. 33. S739–S740. 1 indexed citations

Adenis, Antoine, Samuel Le Sourd, X. Mirabel, et al.. (2022). Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.. Journal of Clinical Oncology. 40(16_suppl). 4015–4015. 2 indexed citations

Campillo‐Gimenez, Boris, Samuel Le Sourd, Marc Pracht, et al.. (2021). ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers. 13(15). 3794–3794. 14 indexed citations

Baère, Thierry de, Marc Pracht, Y. Rolland, et al.. (2021). Results from the phase I dose-escalation study of the radiation enhancer NBTXR3 for the treatment of HCC and liver metastases.. Journal of Clinical Oncology. 39(3_suppl). 319–319. 5 indexed citations

Boilève, Alice, Aline Maillard, Mathilde Wagner, et al.. (2020). Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. BMC Cancer. 20(1). 74–74. 12 indexed citations

Neuzillet, Cindy, Andrea Casadei‐Gardini, Bertrand Brieau, et al.. (2020). Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer. 147(11). 3177–3188. 17 indexed citations

10.

Palard, Xavier, Marc Pracht, Samuel Le Sourd, et al.. (2020). Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. CardioVascular and Interventional Radiology. 43(8). 1175–1181. 15 indexed citations

11.

Pracht, Marc, Y. Rolland, Thierry de Baère, et al.. (2020). Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: A phase I/II trial.. Journal of Clinical Oncology. 38(4_suppl). 537–537. 1 indexed citations

12.

Pracht, Marc, Samuel Le Sourd, Alexandra Lespagnol, et al.. (2018). Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. Bulletin du Cancer. 105. S80–S91. 1 indexed citations

13.

Palard, Xavier, Yan Rolland, Samuel Le Sourd, et al.. (2018). A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging. 45(10). 1731–1741. 22 indexed citations

14.

Artru, Pascal, Estelle Le Pabic, Marc Pracht, et al.. (2017). Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease. 49(6). 692–696. 23 indexed citations

15.

Edeline, Julien, Yann Touchefeu, Boris Guiu, et al.. (2017). Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). Annals of Oncology. 28. v242–v242. 2 indexed citations

16.

Palard, Xavier, Julien Edeline, Yan Rolland, et al.. (2017). Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 45(3). 392–401. 61 indexed citations

17.

Brunot, Angélique, Florence Le Roy, Samuel Le Sourd, et al.. (2017). Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib’s Toxicities in Hepatocellular Carcinoma. Cancer Nursing. 41(5). 418–423. 15 indexed citations

18.

Brunot, Angélique, Samuel Le Sourd, Marc Pracht, & Julien Edeline. (2016). Hepatocellular carcinoma in elderly patients: challenges and solutions. Journal of Hepatocellular Carcinoma. 3. 9–9. 31 indexed citations

19.

Laffont, Sophie, Yan Rolland, Valérie Ardisson, et al.. (2015). Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization. European Journal of Nuclear Medicine and Molecular Imaging. 43(5). 824–831. 15 indexed citations

20.

Edeline, Julien, Laurence Crouzet, Samuel Le Sourd, et al.. (2014). Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemotherapy and Pharmacology. 75(1). 215–219. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact